These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 26893543)
1. Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. Song L; Zhang Z; Hu R; Cheng J; Li L; Fan Q; Wu N; Gan J; Zhou M; Liu Z Drug Des Devel Ther; 2016; 10():547-55. PubMed ID: 26893543 [TBL] [Abstract][Full Text] [Related]
2. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282 [TBL] [Abstract][Full Text] [Related]
3. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease. Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768 [TBL] [Abstract][Full Text] [Related]
4. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846 [TBL] [Abstract][Full Text] [Related]
5. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284 [TBL] [Abstract][Full Text] [Related]
6. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia. Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266 [TBL] [Abstract][Full Text] [Related]
7. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632 [TBL] [Abstract][Full Text] [Related]
8. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628 [TBL] [Abstract][Full Text] [Related]
10. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947 [TBL] [Abstract][Full Text] [Related]
11. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957 [TBL] [Abstract][Full Text] [Related]
12. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801 [TBL] [Abstract][Full Text] [Related]
13. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease. Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677 [No Abstract] [Full Text] [Related]
14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677 [TBL] [Abstract][Full Text] [Related]
15. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model. Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664 [TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168 [TBL] [Abstract][Full Text] [Related]
20. Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats. Gan J; Qi C; Liu Z Drug Des Devel Ther; 2015; 9():2119-28. PubMed ID: 25926720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]